E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Phase 2 Recruiting 20 enrolled Christian Hinrichs Iovance Biotherapeutics, Inc. · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

Timeline

Start: 2023-03-07
Primary completion: 2027-01-01
Completion: 2027-01-01

Publications

Background Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanovic S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021 Mar;27(3):419-425. doi: 10.1038/s41591-020-01225-1. Epub 2021 Feb 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	T-Cell Therapy	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—
Background	aldesleukin	Protein / enzyme biologic	720000 iu/kg	Intravenous

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Summary

Timeline

Publications

Drugs

Indications